10-Q: Philip Morris International Reports Strong Second Quarter Earnings Driven by Smoke-Free Products

Philip Morris International's second-quarter results show significant growth in net revenues and earnings per share, fueled by the increasing adoption of smoke-free products.

Summary

• Philip Morris International (PMI) reported a 7.5% increase in net revenues for the six months ended June 30, 2024, reaching $18.3 billion.
• Excluding currency and acquisitions, net revenues increased by 10.8%, driven by favorable pricing and volume/mix, particularly in smoke-free products.
• Diluted earnings per share (EPS) for the six months increased by 27.5% to $2.92, with a significant contribution from operational improvements.
• The company's smoke-free products accounted for $7.0 billion of net revenues in the first six months of 2024.
• For the three months ended June 30, 2024, net revenues increased by 5.6% to $9.5 billion, with a 9.6% increase excluding currency and acquisitions.
• Diluted EPS for the quarter increased by 52.5% to $1.54, with a 70.3% increase excluding unfavorable currency impacts.
• The company's total cigarette and heated tobacco unit shipment volume increased by 2.8% for the six months and 2.5% for the quarter.
• Oral smoke-free product volume increased by 31.2% for the six months and 23.5% for the quarter, primarily driven by nicotine pouches.
• PMI's effective tax rate for the six months ended June 30, 2024 was 24.2%, and 23.7% for the three months ended June 30, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic progress in smoke-free products. However, there are some concerns about currency headwinds, increased costs, and regulatory risks, which prevent a perfect score.

Positives

• Strong growth in smoke-free product revenues and volumes indicates successful transformation efforts.
• Significant increase in diluted EPS demonstrates improved profitability.
• Reacquisition of IQOS commercialization rights in the U.S. provides a clear path for future growth.
• Positive adjusted in-market sales for heated tobacco units, particularly in Japan and Europe.
• The company has a strong cash position and expects to generate approximately $11 billion in operating cash flow for the full year 2024.

Negatives

• Unfavorable currency movements, particularly against the Egyptian pound, Japanese yen, and Russian ruble, negatively impacted net revenues and earnings.
• Higher interest expenses due to increased debt levels and interest rates.
• Increased marketing, administration, and research costs, including higher amortization of intangibles.
• The company experienced a decrease in operating income in the Americas region.
• The company has been impacted by the EU single-use plastics directive, which has increased manufacturing costs.

Risks

• The company faces regulatory risks, including potential restrictions on the sale and marketing of smoke-free products.
• The company is exposed to litigation risks related to tobacco and nicotine products.
• The company is subject to risks related to illicit trade, including counterfeiting and contraband.
• The company is exposed to risks related to cybersecurity incidents and data breaches.
• The company is subject to risks related to the war in Ukraine, including potential disruptions to supply chains and operations.
• The company is subject to risks related to inflation, which may increase operating and financing costs and reduce demand for products.
• The company is subject to risks related to the volatility of currency exchange rates.

Future Outlook

PMI expects its 2024 performance to be favorably impacted by accelerated total volume growth and pricing, despite currency headwinds. The company anticipates strong growth for ZYN and increasing profitability of IQOS due to operating leverage and manufacturing efficiencies.

Management Comments

• The company is actively delivering a smoke-free future.
• PMI is evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
• The Swedish Match acquisition is a key milestone in PMIs transformation to becoming a smoke-free company.
• PMI now holds the full rights to commercialize IQOS in the U.S.

Industry Context

This announcement reflects a broader industry trend of tobacco companies shifting towards smoke-free alternatives due to increasing health concerns and regulatory pressures on traditional cigarettes. PMI's focus on smoke-free products aligns with this trend and positions the company for future growth in a changing market.

Comparison to Industry Standards

• PMI's performance in the smoke-free category, particularly with IQOS and ZYN, is outpacing many of its competitors, such as British American Tobacco and Japan Tobacco, who are also investing in smoke-free alternatives.
• The company's focus on scientific substantiation and regulatory approvals for its smoke-free products sets it apart from some competitors who may be facing regulatory challenges.
• PMI's strategic acquisitions, such as Swedish Match and Vectura Fertin Pharma, are aimed at diversifying its portfolio and creating a competitive advantage in the wellness and healthcare sectors, which is a less common strategy among its peers.
• While other companies are also experiencing growth in smoke-free products, PMI's scale and global reach provide a significant advantage in terms of market penetration and brand recognition.
• The company's financial performance, particularly in terms of revenue growth and EPS, is generally strong compared to industry averages, although currency fluctuations and specific market conditions can create variability.

Legal Proceedings

• The company is involved in various legal proceedings related to tobacco and nicotine products.
• The company is facing litigation related to its oral nicotine products in the U.S.
• The company is subject to governmental investigations on a range of matters, including tax, customs, antitrust, advertising, and labor practices.

Related Party Transactions

• PMI has related-party transactions with Megapolis Group, United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) (TTI), and Godfrey Phillips India Ltd (GPI).

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and increased dividends.
• Employees may benefit from the company's growth and investment in new technologies.
• Customers will have access to a wider range of smoke-free products.
• Suppliers may benefit from increased demand for raw materials and components.
• Creditors will benefit from the company's strong cash flow and financial position.

Next Steps

• PMI will continue to focus on expanding its smoke-free product portfolio and commercialization efforts.
• The company will continue to monitor and address regulatory developments and challenges.
• PMI will continue to invest in manufacturing capacity and supply chain optimization.
• The company will continue to monitor and mitigate the impact of inflation and currency fluctuations.

Key Dates

Keywords

smoke-free products, IQOS, ZYN, heated tobacco, nicotine pouches, financial results, net revenues, earnings per share, operating income, tobacco, vaping, oral nicotine, regulation, litigation, currency, inflation